广东威尔医院,wellclinic,威尔医院骨科
医院公益
特邀专家

门诊时间(无假日医院)
早上8:00 - 晚上21:00

紧急联系电话:020-38063333

 

夏洪平

新加坡国立癌症中心项目负责人
维也纳医科大学癌症中心项目负责人

个人简介
夏洪平, 男, 医师/博士/教授,博士生导师, 国家“千人计划”青年项目和“江苏省特聘教授” 获得者。 1982 年出生于安徽省, 2011 年毕业于香港大学获博士学位, 曾在维也纳医科大学癌症中心和新加坡国立癌症中心从事恶性肿瘤的转化医学与精准治疗研究,已作为项目负责人( Principle Investigator, PI)主持国家自然科学基金,National Medical Research Council ( NMRC,新加坡国家医学研究委员会)基金和Singhealth Foundation(新加坡保健服务集团基金)课题多项,在 Hepatology (IF: 12.08),ACS Nano (IF: 13.33), Gut (IF: 14.92), Journal of Hepatology (IF: 11.34), Nanoscale (IF:7.8), Neuro-Oncology (IF: 7.4) 和 The Journal of Biological Chemistry (IF: 5.12) 等国际期刊杂志上发表相关论著三十余篇 (其中第一作者/通讯作者论文 28 篇),影响因子( IF)>10的 5 篇, IF>5 的 16 篇,论文引用>1500 次, 申请专利多项。于 2016 年入选国家“千人计划”青年项目和“江苏省特聘教授”,加盟南京医科大学基础医学院病理学系和南京医科大学附属逸夫医院临床病理与检验中心组建课题组,研究方向将主要集中在恶性肿瘤分子病理,分子影像与代谢,早期诊断和个性化靶向精准治疗及纳米介导的分子生物靶向药物研发。 目前担任国家自然科学基金通讯评审专家和 World Journal ofGastroenterology (IF: 2.547), Hepatoma Research 等杂志的 Editorial Board Member,也是多个杂志如 Annals of Oncology (IF: 7.384), Oncotarget (IF: 6.6), Hepatology (IF:12.08) 和Nano Letters (IF: 13.6)等的特约审稿人。

学术兼职:
美国癌症协会会员;
环太平洋大学联盟博士生协会执行委员会委员;
美国华人医药科学家协会会员;
维也纳医科大学青年科学家协会会员;
新加坡国立癌症中心青年科学家协会会员;
新加坡中国学生学者联合会会员;

近年部分代表性论文著作:
(1) Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LL, Hui KM. EDIL3 isa novel regulator of epithelial mesenchymal transition controlling early recurrence ofhepatocellular carcinoma. J Hepatol. 2015 Oct; 63(4):863-73. (IF:11.34)
(2) Ling D*, Xia H*, et al. pH-Sensitive Nanoformulated Triptolide as a TargetedTherapeutic Strategy for Hepatocellular Carcinoma. ACS Nano. 2014 Aug26;8(8):8027-39. (*Co-first author). (IF: 13.33).
(3) Xia H, et al. MiR-216a/217-induced epithelial-mesenchymal transition targets PTENand SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology.2013 Aug; 58(2):629-41. (IF: 12.08).
(4) Xia H, et al. pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistanceand Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Cent. Sci., 2016, 2(11), pp 802–811.
(5) Xia H, et al. MELK is an oncogenic kinase essential for early hepatocellular
carcinoma recurrence. Cancer Lett. 2016 Dec 1;383(1):85-93. (IF: 5.99)2
(6) Chen J, Xia H, et al. ECT2 regulates the Rho/ERK signalling axis to promote earlyrecurrence in human hepatocellular carcinoma. J Hepatol. 2015 Jun;62(6):1287-95.(IF: 11.34).
(7) Chen J, Muthukumar Rajasekaran, Xia H,….The microtubule-associated proteinPRC1 promotes early recurrence of hepatocellular carcinoma in association with theWnt/β-catenin signalling pathway. Gut. 2016 Sep;65(9):1522-34. (IF: 14.92).
(8) Han J*, Xia H*, Wu Y, Kong SN, Deivasigamani A, Xu R, Hui KM, Kang Y.Single-layer MoS2 nanosheet grafted upconversion nanoparticles for near-infraredfluorescence imaging-guided deep tissue cancer phototherapy. Nanoscale. 2016 Apr14;8(15):7861-5. (*Co-first author). (IF: 7.8).
(9) Li S, …, Xia H#. Protein tyrosine phosphatase PTPN3 promotes drug resistance andstem cell-like characteristics in ovarian cancer. Sci Rep. 2016 Nov 11;6:36873. doi:10.1038/srep36873. (#Corresponding author) (IF:5.23).
(10) Jiang X, … , Xia H#. HSP47 promotes glioblastoma stem-like cell survival bymodulating tumor microenvironment extracellular matrix through TGF-β pathway.ACS Chem Neurosci. 2016. PMID:27696866 (#Corresponding author) (IF:4.34).
(11) Miao L, … , Xia H#, Wang Y. Loss of long noncoding RNA FOXF1-AS1 regulatesepithelial-mesenchymal transition, stemness and metastasis of non-small cell lungcancer cells. Oncotarget. 2016 Aug 26. doi: 10.18632/oncotarget.11630(#Corresponding author) (IF:5.01).
(12) Jiang X, … , Xia H #. Increased level of H19 long noncoding RNA promotesinvasion, angiogenesis, and stemness of glioblastoma cells. J Neurosurg. 2015 Aug14:1-8. (#Corresponding author) (IF:3.74)
(13) Xia, H, et al. The Over-Expression of Survivin Enhances the ChemotherapeuticEfficacy of YM155 in Human Hepatocellular Carcinoma. Oncotarget. 2015 Mar 20;6(8):5990-6000. (IF: 5.01).
(14) Shen L, …, Xia H#, Zhuang Z. Long noncoding RNA MALAT1 promotes brainmetastasis by inducing epithelial-mesenchymal transition in lung cancer. JNeurooncol. 2015; 121 (1):101-8. (#Corresponding author) (IF: 3.1).
(15) Hu M, … , Xia H#. Loss of miR-1258 contributes to carcinogenesis and progressionof liver cancer through targeting CDC28 protein kinase regulatory subunit 1B.Oncotarget. 2016 Jul 12;7(28):43419-43431. (#Corresponding author) (IF: 5.01).
(16) Xia H, … , Jiang X. MiR-218 sensitizes glioma cells to apoptosis and inhibitstumorigenicity by regulating ECOP-mediated suppression of NF-κB activity.Neuro-oncology, 2013. 15(4): p. 413-422. (IF: 6.18)
(17) Wang Y*, Xia H*, et al. Axl-altered microRNAs regulate tumorigenicity andgefitinib resistance in lung cancer. Cell Death Dis. Cell Death Dis. 2014 May15;5:e1227. (*Co-first author). (IF: 6.044)
(18) Xia H, et al. Mechanism of cancer drug resistance and the involvement ofnoncoding RNAs. Curr Med Chem. 2014; 21(26):3029-41. (IF: 4.07)
(19) Xia H, et al. Loss of brain-enriched miR-124 enhances the stem-like traits andinvasiveness of glioma cells. J Biol Chem. 2012 Mar 23;287(13):9962-71. (IF: 5.12)
(20) Xia H, et al. miR-200a regulates epithelial-mesenchymal to stem-like transition viaZEB2 and beta-catenin signaling. J Biol Chem. 2010 Nov 19;285(47):36995-7004.(IF: 5.12)

 

 
分享到:
  • 国家卫生部
  • 国家食药监局
  • 中国医师协会
  • 中华医学会
  • 上海卫生局
  • 世界卫生组织